Recombinant Mycoplasma genitalium Elongation factor G (fusA), partial

What is the role of Elongation Factor G (fusA) in Mycoplasma genitalium protein synthesis?

Elongation Factor G (FusA) in Mycoplasma genitalium functions as a critical component of the bacterial protein synthesis machinery. The protein acts during the elongation phase of translation, catalyzing the translocation of peptidyl-tRNA from the A-site to the P-site of the ribosome after peptide bond formation. This process is essential for protein synthesis and bacterial survival. FusA interacts directly with the ribosome to facilitate this translocation, making it an attractive target for antimicrobial agents like fusidic acid. Fusidic acid binds to FusA and inhibits protein synthesis by preventing its release from the ribosome, thereby disrupting the elongation cycle . M. genitalium FusA shares structural and functional similarities with FusA proteins from other bacteria, though with specific sequence variations that can impact antibiotic binding and effectiveness.

How conserved is the fusA gene among Mycoplasma genitalium strains?

FusA is remarkably conserved among M. genitalium strains, demonstrating the essential nature of this protein for bacterial survival. Analysis of 23 fully genome-sequenced M. genitalium strains revealed that FusA exhibits variability at only two residues: position 204 (V or A) and position 540 (T or A) . These variable amino acids are located distant from the fusidic acid binding pocket and are not implicated in fusidic acid resistance. The high conservation extends to critical residues F435 and Q660, which are involved in fusidic acid binding and resistance when mutated. This conservation pattern strongly suggests that most M. genitalium strains express a fusidic acid-susceptible FusA protein . The conservation extends beyond M. genitalium, with F435 and Q660 being conserved across more than 20 different Mycoplasma species, highlighting the evolutionary pressure to maintain the structure and function of this essential protein.

What structural features of M. genitalium FusA are important for fusidic acid binding?

The structural features of M. genitalium FusA that facilitate fusidic acid binding have been elucidated through predictive modeling and resistance studies. The AlphaFold-predicted structure of M. genitalium FusA (PDB P47335) shows significant similarity to Staphylococcus aureus FusA, which has been co-crystallized with fusidic acid . Key structural elements include:

These structural insights reveal that fusidic acid's mechanism of action involves binding to a specific pocket in FusA, preventing the conformational changes required for its normal function in protein synthesis . Mutations that alter these structural features can lead to resistance while potentially impacting the protein's normal function, as evidenced by the reduced growth rate observed in strains with certain FusA mutations.

How do specific mutations in M. genitalium fusA confer resistance to fusidic acid?

Research has identified several specific mutations in M. genitalium FusA that confer resistance to fusidic acid through distinct mechanisms. In laboratory-selected fusidic acid-resistant mutants, the following key mutations have been characterized:

• F435Y mutation: Located in the fusidic acid binding pocket, this mutation directly affects drug binding and confers resistance. Notably, the F435Y mutant (FusR8) exhibited significantly impaired growth with a doubling time of 15.2 hours compared to 11.5 hours for wild-type strains (p = 0.006) . This suggests that this mutation, while providing resistance, imposes a significant fitness cost.

• Q660R/K mutations: These mutations were identified in multiple resistant isolates (FAR1, FAR2, FAR3, and FAR5) and likely affect the interaction of EF-G with the ribosome rather than directly interfering with fusidic acid binding . These mutants maintained normal growth rates with doubling times ranging from 11.5 to 12.5 hours, suggesting minimal fitness costs .

The resistance mechanism involves structural alterations that prevent fusidic acid from effectively binding to FusA or from stabilizing the FusA-ribosome complex. Interestingly, no mutants resistant to >10 μg/mL fusidic acid were obtained in laboratory selection experiments, and the frequency of resistance decreased at higher drug concentrations (resistance rate ~5 × 10⁻⁷ on 10 μg/mL and <3 × 10⁻⁷ on 25 and 50 μg/mL) . Furthermore, resistant colonies on 10 μg/mL showed atypical morphology compared to the characteristic "fried egg" appearance of normal M. genitalium colonies .

What methodologies are most effective for producing and purifying recombinant M. genitalium FusA for structural studies?

Producing recombinant M. genitalium FusA for structural and functional studies requires specialized approaches due to the unique characteristics of Mycoplasma proteins. The following methodological framework is recommended:

• Expression system selection:

  • E. coli BL21(DE3) with codon optimization for the rare codons found in Mycoplasma is typically the most efficient system

  • Fusion tags such as His6, GST, or MBP can improve solubility and facilitate purification

  • Consider using expression vectors with tight regulation (pET series) to minimize toxicity effects

• Protein solubility enhancement:

  • Expression at lower temperatures (16-20°C) after induction

  • Co-expression with chaperones (GroEL/GroES system)

  • Use of solubility enhancers such as sorbitol (0.5-1 M) or arginine (50-100 mM) in culture media

• Purification strategy:

  • Initial capture via affinity chromatography (Ni-NTA for His-tagged constructs)

  • Intermediate purification using ion exchange chromatography

  • Polishing step with size exclusion chromatography to ensure homogeneity

  • Include reducing agents (1-5 mM DTT or TCEP) throughout purification to maintain cysteine residues in reduced state

• Quality control assessments:

  • Dynamic light scattering to assess homogeneity and aggregation state

  • Differential scanning fluorimetry to optimize buffer conditions

  • Analytical ultracentrifugation to confirm monomeric state

  • Activity assays to verify functional integrity

For structural studies specifically, the purified protein should be concentrated to 5-10 mg/mL in a buffer containing 20 mM HEPES pH 7.5, 150 mM NaCl, and 5% glycerol. For co-crystallization with fusidic acid, protein-ligand complexes should be prepared with a 2-5 fold molar excess of fusidic acid prior to crystallization screening.

How can site-directed mutagenesis of recombinant M. genitalium FusA inform antimicrobial development?

Site-directed mutagenesis of recombinant M. genitalium FusA represents a powerful approach for understanding resistance mechanisms and guiding antimicrobial development. A comprehensive mutagenesis strategy should include:

• Resistance-associated mutations:

  • Introduction of known resistance mutations (F435Y, Q660R/K) into wild-type FusA to confirm their role in resistance

  • Characterization of binding kinetics (using isothermal titration calorimetry or surface plasmon resonance) to quantify how these mutations affect fusidic acid binding affinity

  • Structural studies of mutant proteins to visualize conformational changes

• Binding pocket exploration:

  • Systematic mutagenesis of residues in and around the predicted fusidic acid binding pocket

  • Creation of a comprehensive binding pocket map with mutation-function relationships

  • Identification of residues that might be targeted for improved drug binding or to overcome resistance

• Functional domain analysis:

  • Mutations in domains involved in GTP binding and hydrolysis

  • Alterations to residues involved in ribosome interaction

  • Modifications to regions involved in conformational changes during translocation

• Cross-resistance assessment:

  • Testing how fusA mutations affect susceptibility to other translation inhibitors

  • Evaluating if fusidic acid-resistant mutants maintain susceptibility to other antibiotics (studies show that fusidic acid-resistant mutants maintained susceptibility to doxycycline and moxifloxacin)

These mutagenesis studies provide critical insights for drug development by:

• Identifying regions less prone to resistance-conferring mutations

• Guiding the design of fusidic acid derivatives that maintain activity against resistant strains

• Revealing potential combination therapy strategies, as fusidic acid resistance does not confer cross-resistance to other antibiotics like doxycycline and moxifloxacin

What in vitro assays can measure the impact of mutations on M. genitalium FusA function?

Several specialized in vitro assays can quantitatively assess how mutations affect M. genitalium FusA function and antimicrobial susceptibility:

• GTPase activity assays:

  • Malachite green phosphate detection assay to measure inorganic phosphate release

  • Coupled enzyme assays using pyruvate kinase and lactate dehydrogenase with NADH oxidation monitoring

  • [γ-³²P]GTP hydrolysis with thin-layer chromatography separation

• Ribosome binding assays:

  • Filter binding assays using purified ribosomes and radiolabeled FusA

  • Fluorescence polarization using fluorescently labeled FusA or ribosomes

  • Surface plasmon resonance to measure association/dissociation kinetics

• Translation efficiency measurements:

  • In vitro translation systems (PURE system adapted for Mycoplasma) with luciferase reporter

  • Poly(U)-directed poly(Phe) synthesis assays

  • Ribosome translocation assays using fluorescently labeled tRNAs

• Thermal stability assessments:

  • Differential scanning fluorimetry to measure protein stability changes

  • Circular dichroism to assess secondary structure alterations

  • Hydrogen-deuterium exchange mass spectrometry to evaluate conformational dynamics

• Drug binding measurements:

  • Isothermal titration calorimetry to determine binding thermodynamics

  • Microscale thermophoresis for binding affinity determination

  • Fluorescence quenching to monitor direct interaction with fusidic acid

For comparative analysis, wild-type and mutant FusA proteins should be assessed in parallel under identical conditions, with careful attention to enzyme concentrations and reaction kinetics. These assays provide quantitative data on how specific mutations affect various aspects of FusA function, helping researchers understand both the mechanisms of resistance and the potential fitness costs associated with these mutations.

How does fusidic acid resistance in M. genitalium compare to resistance mechanisms in other bacteria?

Fusidic acid resistance mechanisms in M. genitalium show both similarities and important differences compared to those observed in other bacterial species:

• Chromosomal mutations in fusA:

  • M. genitalium: Resistance primarily occurs through specific mutations in fusA (F435Y, Q660R/K)

  • S. aureus: While fusA mutations do occur, resistance more commonly develops through horizontal acquisition of fusB, fusC, or fusD genes that protect FusA from fusidic acid inhibition

  • This difference likely reflects the limited horizontal gene transfer options available to the minimal genome of M. genitalium

• Mutation locations and effects:

  • M. genitalium: Key resistance mutations occur at F435 (in the fusidic acid binding pocket) and Q660 (affecting ribosome interaction)

  • S. aureus: Shows a wider variety of resistance-associated mutations distributed throughout the fusA gene

  • Both organisms demonstrate functional consequences of resistance mutations, with some conferring growth disadvantages

• Resistance frequencies:

  • M. genitalium: Resistance rates are relatively low (~5 × 10⁻⁷ on 10 μg/mL and <3 × 10⁻⁷ on 25 and 50 μg/mL fusidic acid)

  • S. aureus: Shows higher spontaneous resistance rates (10⁻⁶ at 2× MIC versus 10⁻⁸ at 16× MIC)

  • Both species demonstrate concentration-dependent resistance development

• Cross-resistance patterns:

  • M. genitalium: Fusidic acid-resistant mutants maintain susceptibility to other antibiotics such as doxycycline and moxifloxacin

  • Similarly, strains resistant to azithromycin and/or moxifloxacin retain susceptibility to fusidic acid

  • This suggests independent resistance mechanisms with minimal overlap

This comparative analysis suggests that fusidic acid may be particularly valuable for treating M. genitalium infections due to the limited resistance mechanisms available to this organism, the fitness costs associated with some resistance mutations, and the lack of cross-resistance with other commonly used antibiotics.

How can recombinant M. genitalium FusA be used to screen potential antimicrobial compounds?

Recombinant M. genitalium FusA provides an excellent platform for screening and identifying novel antimicrobial compounds. A comprehensive screening approach should include:

• High-throughput binding assays:

  • Fluorescence polarization assays using labeled fusidic acid derivatives

  • Thermal shift assays to detect compounds that stabilize FusA

  • Competition assays against labeled fusidic acid to identify compounds binding to the same site

• Functional inhibition screens:

  • GTPase activity inhibition assays

  • Ribosome binding interference assays

  • In vitro translation inhibition using purified components

• Screening strategies for resistance-bypassing compounds:

  • Parallel screening against wild-type and resistant FusA variants (F435Y, Q660R/K)

  • Identification of compounds that maintain activity against resistant mutants

  • Structure-activity relationship studies guided by binding site analysis

• Whole-cell validation approaches:

  • Growth inhibition assays using M. genitalium strains (wild-type and resistant)

  • Time-kill studies to determine bactericidal versus bacteriostatic activity

  • Selection for resistance to identify novel resistance mechanisms

When implementing these screening approaches, researchers should consider:

• Testing compounds at concentrations achievable in human plasma (comparable to fusidic acid's clinically relevant concentrations)

• Assessing activity against a panel of M. genitalium clinical isolates with different resistance profiles

• Evaluating compounds for their ability to achieve bactericidal killing similar to fusidic acid (≥10 μg/mL for 48h)

These screening approaches can identify compounds with improved properties compared to fusidic acid, including enhanced activity against resistant strains, more favorable pharmacokinetics, or reduced potential for resistance development.

What are the challenges in developing in vitro translation systems using M. genitalium components?

Developing in vitro translation systems using M. genitalium components presents several unique challenges that researchers must address:

• Component purification difficulties:

  • M. genitalium's slow growth rate (doubling time 11.5-12.5 hours for wild-type) makes large-scale cultivation challenging

  • Minimal genome lacks certain metabolic pathways, necessitating complex media requirements

  • Many translation components may require co-expression of chaperones for proper folding

• Reconstitution challenges:

  • Limited knowledge of M. genitalium-specific translation factor requirements

  • Potential need for specific post-translational modifications

  • Optimization of ion concentrations and buffer conditions specific to M. genitalium proteins

• Technical adaptation requirements:

  • Modification of existing PURE system protocols to accommodate M. genitalium components

  • Adjustment of reaction conditions for the AT-rich codon usage of M. genitalium

  • Development of specialized reporter systems compatible with M. genitalium translation machinery

• Validation considerations:

  • Comparative analysis with other well-established in vitro translation systems

  • Correlation of in vitro results with in vivo antimicrobial activity

  • Verification that inhibition patterns match those observed in whole-cell systems

To overcome these challenges, researchers can employ the following strategies:

• Initial hybrid systems using E. coli components with key M. genitalium factors (like FusA) substituted

• Gradual replacement of components to create increasingly authentic M. genitalium systems

• Application of recent advances in cell-free protein synthesis technology

• Utilization of synthetic biology approaches to optimize expression and activity

Despite these challenges, a functioning M. genitalium in vitro translation system would provide unprecedented opportunities for studying antibiotic action mechanisms and screening for novel inhibitors targeting this clinically important pathogen.

How can structural information about M. genitalium FusA inform drug design efforts?

Structural information about M. genitalium FusA provides crucial insights that can guide rational drug design efforts:

• Structure-based drug design approaches:

  • Virtual screening against the fusidic acid binding pocket of M. genitalium FusA

  • Fragment-based drug design targeting key interaction sites

  • Molecular dynamics simulations to identify transient binding pockets

  • Docking studies to optimize binding interactions

• Resistance mechanism insights:

  • Structural analysis of how F435Y and Q660R/K mutations alter binding site geometry

  • Identification of alternative binding sites less affected by known resistance mutations

  • Design of compounds that can overcome resistance mechanisms through alternative binding modes

• FusA conformational dynamics exploitation:

  • Targeting different conformational states of FusA during the translocation cycle

  • Designing compounds that lock FusA in non-productive conformations

  • Exploiting protein-protein interaction surfaces between FusA and the ribosome

• Comparative structural analysis:

  • Leveraging the AlphaFold-predicted structure of M. genitalium FusA (PDB P47335)

  • Comparing with S. aureus FusA co-crystallized with fusidic acid to identify conserved and divergent features

  • Identifying M. genitalium-specific structural features that could be selectively targeted

Key structural features to consider include:

• The fusidic acid binding pocket containing F435

• Regions involved in ribosome interaction, including Q660

• GTP binding and hydrolysis domains

• Conformational change regions essential for translocation function

This structural information enables the rational design of:

• Modified fusidic acid derivatives with enhanced binding to wild-type and resistant FusA

• Novel chemical scaffolds targeting the same functional sites but with different binding modes

• Allosteric inhibitors that bind to sites distant from the fusidic acid binding pocket

What considerations are important when evaluating fusidic acid as a treatment for drug-resistant M. genitalium infections?

Evaluating fusidic acid as a treatment for drug-resistant M. genitalium infections requires consideration of several key factors:

• Activity profile against resistant strains:

  • Fusidic acid demonstrates MICs ranging from 0.31 to 4 μg/mL against various M. genitalium strains, including those resistant to macrolides and fluoroquinolones

  • Clinical isolates resistant to azithromycin and/or moxifloxacin maintain susceptibility to fusidic acid, suggesting value for multidrug-resistant infections

  • Time-kill data indicate bactericidal activity at ≥10 μg/mL for 48h, well below plasma concentrations achieved with typical treatment regimens

• Resistance development potential:

  • Resistance rates are relatively low (~5 × 10⁻⁷ on 10 μg/mL fusidic acid)

  • No mutants resistant to >10 μg/mL fusidic acid were obtained in laboratory selection experiments

  • Some resistance mutations (F435Y) impair growth, potentially reducing their clinical significance

• Pharmacokinetic/pharmacodynamic considerations:

  • Standard fusidic acid dosing achieves plasma concentrations above the bactericidal concentration for M. genitalium

  • Unlike in S. aureus treatment, co-administration with rifampin would be ineffective since Mollicutes are intrinsically resistant to rifampin

  • Optimal dosing strategies may differ from those established for other infections

• Clinical trial design factors:

  • Need for molecular diagnostics to confirm M. genitalium infection and characterize resistance profile

  • Appropriate endpoints (microbiological cure versus symptom resolution)

  • Monitoring for resistance development during and after treatment

  • Comparison with current treatment recommendations for multi-resistant M. genitalium

Given fusidic acid's long history of clinical use for other indications, its established safety profile, and its activity against multidrug-resistant M. genitalium, it represents a promising treatment option that warrants clinical evaluation, particularly for patients with limited treatment alternatives .

How can recombinant FusA be used to develop diagnostic tools for detecting fusidic acid resistance in clinical M. genitalium isolates?

Recombinant M. genitalium FusA can serve as the foundation for developing advanced diagnostic tools to detect fusidic acid resistance in clinical isolates:

• Molecular diagnostic approaches:

  • PCR-based detection of known resistance mutations (F435Y, Q660R/K) in the fusA gene

  • Development of multiplex assays that simultaneously detect M. genitalium and resistance mutations in fusA, MgPa, 23S rRNA, and parC genes

  • Next-generation sequencing protocols focusing on resistance hotspots

  • CRISPR-Cas-based detection systems for specific fusA mutations

• Structural biology-based diagnostics:

  • Development of antibodies or aptamers that specifically recognize wild-type versus mutant FusA proteins

  • Lateral flow assays using these recognition elements for point-of-care testing

  • Protein-based biosensors that detect conformational differences between wild-type and resistant FusA variants

• Functional diagnostic methods:

  • Phenotypic assays using recombinant FusA to measure fusidic acid binding affinity

  • Reporter systems that reflect translation inhibition in the presence of clinical isolate components

  • Cell-free translation systems incorporating patient-derived FusA to assess functional inhibition

• Bioinformatic approaches:

  • Development of databases cataloging fusA mutations and associated resistance profiles

  • Machine learning algorithms to predict resistance from partial sequence data

  • Evolutionary models to predict emerging resistance mechanisms

Implementation considerations include:

• Need for rapid turnaround time to guide clinical decision-making

• Balance between comprehensive resistance profiling and practical clinical utility

• Integration with existing diagnostic platforms for sexually transmitted infections

• Correlation of molecular markers with clinical treatment outcomes

These diagnostic approaches would facilitate personalized treatment selection, antimicrobial stewardship, and surveillance for emerging resistance patterns in this difficult-to-treat pathogen.

What are promising avenues for developing fusidic acid derivatives with enhanced activity against resistant M. genitalium strains?

Several promising strategies exist for developing next-generation fusidic acid derivatives with improved activity against resistant M. genitalium strains:

• Structure-guided modifications:

  • Alterations to the fusidane core structure to enhance binding to mutant FusA proteins

  • Side chain modifications to create additional binding interactions that compensate for resistance mutations

  • Development of hybrid molecules incorporating structural elements from other translation inhibitors

• Resistance-bypassing approaches:

  • Design of compounds that maintain binding to F435Y mutants by exploiting alternative interaction sites

  • Development of derivatives that target regions of FusA distant from common resistance mutations

  • Creation of dual-action molecules that simultaneously target multiple sites on FusA

• Pharmacokinetic optimization:

  • Modifications to enhance tissue penetration into the genital tract

  • Formulation strategies to achieve sustained local concentrations

  • Prodrug approaches to improve bioavailability and reduce dosing frequency

• Combination strategies:

  • Identification of synergistic combinations with other antibiotics active against M. genitalium

  • Development of hybrid molecules combining fusidic acid with other antibiotic classes

  • Exploration of non-antibiotic adjuvants that enhance fusidic acid activity or suppress resistance development

• Drug delivery innovations:

  • Nanoparticle formulations for targeted delivery to infection sites

  • Controlled-release systems for maintaining concentrations above the resistance selection window

  • Topical formulations for local treatment of genital infections

These approaches should leverage the detailed understanding of fusidic acid's binding mode and resistance mechanisms in M. genitalium FusA, while also considering the clinical context of M. genitalium infections. The goal should be to develop compounds that maintain activity against resistant strains while also addressing practical considerations such as dosing convenience and tissue penetration.

How might comparative genomics of FusA across Mycoplasma species inform our understanding of species-specific antibiotic susceptibilities?

Comparative genomics of FusA across Mycoplasma species offers valuable insights into the molecular basis of species-specific antibiotic susceptibilities:

• Conservation patterns and functional implications:

  • F435 and Q660, key residues for fusidic acid binding and resistance in M. genitalium, are conserved across more than 20 Mycoplasma species

  • M. fermentans presents an interesting case study: F435 is conserved across all sequenced strains, but Q660 is replaced by A660 in three of four strains (JER, MF-I1, and M64)

  • These M. fermentans strains show elevated fusidic acid MICs (10-25 μg/mL), suggesting that the Q660A substitution may confer natural resistance

• Evolutionary analysis approaches:

  • Phylogenetic analysis of FusA sequences across Mycoplasma species

  • Identification of position-specific evolutionary rates to detect sites under selective pressure

  • Ancestral sequence reconstruction to understand the evolutionary trajectory of resistance determinants

• Structure-function correlation studies:

  • Homology modeling of FusA from multiple Mycoplasma species

  • Comparative analysis of predicted binding pockets and resistance-associated regions

  • Virtual screening to predict species-specific susceptibility patterns

• Experimental validation strategies:

  • Recombinant expression of FusA from different Mycoplasma species

  • Swapping of domains or specific residues between susceptible and naturally resistant species

  • Correlation of in vitro susceptibility data with FusA sequence variations

This comparative approach would:

• Help predict the susceptibility of difficult-to-culture Mycoplasma species to fusidic acid

• Identify natural variations that confer resistance and could emerge in M. genitalium

• Guide the design of species-selective antibiotics or broader-spectrum agents

• Provide evolutionary context for resistance development in clinical settings

The natural variation in Q660 (to A660) in M. fermentans and its correlation with elevated MICs provides a compelling starting point for understanding how subtle sequence variations can dramatically impact antibiotic susceptibility across Mycoplasma species .